This latest investment into expanding its manufacturing capabilities reinforces the company’s commitment to the U.S. and enhances its global biomanufacturing network.

The acquisition will provide PCI with a large-scale manufacturing hub on the West Coast of the U.S., complementing its existing global facilities.

Significant funds, in series A & B funding rounds, have been raised from leading investors to advance the company’s two first-in-class monoclonal antibodies targeting inflammation, autoimmunity, and fibrosis.

Over the next five years, Roche will invest USD 50 billion to expand and upgrade existing facilities and build new facilities across its Pharmaceutical and Diagnostics Division in the U.S.

The CRO is expanding its headquarters to include a comprehensive laboratory and rodent vivarium, which enhances its preclinical research infrastructure in the U.S.

Biologics CDMO, Wheeler Bio, has successfully raised USD 35 mn in an oversubscribed Series A-1 funding round. The funds will help the company strengthen its biologics’ manufacturing capabilities, such as planning the development of a large-scale facility.

Canadian CDMO, Delpharm, has secured a USD 42 mn investment from the Canadian Government to enhance the production capacity of its injectables manufacturing facility in Montreal, Canada.

Spanish CDMO, Esteve Química, is investing USD 100 mn to expand its U.S. manufacturing capabilities, focusing on increasing production capacity for high potency APIs (HPAPIs) amid increasing market demands for their use.

Innovation, science, and pharmaceutical services partner, Bend Bioscience, is expanding its Gainesville, Georgia facility with the addition of a commercial-scale spray dryer and a Gerteis drug granulation system.

German CDMO, Adragos Pharma, has announced plans to strengthen its presence in Japan by expanding the production capacity of its Kawagoe facility, acquired from Sanofi in 2023. The company plans to increase solid dosage production to one billion tablets, with further investment to reach a two-billion-tablet capacity.

German CDMO, Vetter, has finalized the third expansion phase of its Center for Visual Inspection and Logistics in Ravensburg, Germany, enhancing its capacity for quality control, storage, and logistics for pharmaceutical companies. The updated facility now includes increased storage capabilities for both refrigerated and room-temperature pharmaceuticals, advanced visual inspection systems, and improved logistics processes.

Indian CRDMO, Syngene International has inaugurated its first U.S.-based manufacturing facility in Rockville, Maryland. The 17,000 square-foot cGMP-certified site will strengthen the company’s CDMO capabilities, and focus on biologics manufacturing, including monoclonal antibodies and recombinant proteins for both clinical and commercial-scale production.

API small molecule and antibody-drug conjugate (ADC) manufacturing company, Axplora, has expanded its Le Mans, France, facility with a cutting-edge payload manufacturing workshop. This expansion is part of the France 2030 program to increase commercial revenue by supplying 40% of the world's marketed ADCs and 50-percent of FDA-approved ADCs.

Northern Ireland-based CDMO, Almac Group, has unveiled a USD 83.7mn investment in a 100,000 sq. ft manufacturing facility at its Craigavon headquarters to produce oral treatments across various therapeutic areas that will feature advanced production suites equipped with the latest pharmaceutical manufacturing technology.

German CDMO, Aenova, has announced a USD 22mn investment to upgrade its Bad Aibling, Germany, site. Capacity for its blister packaging lines has been increased to 220 million blisters, annually, whilst a new strip packaging line increased effervescent output to 420 million tablets a year.

Eli Lilly is committing USD 27 bn to build four new manufacturing plants in the United States, to increase domestic production of active pharmaceutical ingredients and injectable therapies.

Advanced drug discovery and development biotech, Eikon Therapeutics, has announced the initial closing of a USD 350 mn Series D funding round, bringing Eikon's total private funding since its 2019 founding to over USD 1.1 bn.

End-to-end CDMO, Enzene, has announced EU GMP certification for its two facilities in Pune, India, to provide commercial-scale microbial and mammalian drug substance supply, and drug product fill/finish and packaging.

CDMO, Bionova Scientific, has opened a 55,000 sq. ft. process development and pilot plant in Fremont, Calif., to enhance early-stage biologics development and support future manufacturing growth and to strengthen the company’s presence in the Bay Area, which generate USD 142 bn annually.

Over the past 18 months, Minnesota-based CDMO Lifecore Biomedical has moved from being a food business to a pure-play sterile injectable fill-finish CDMO. To support its transition, the company announced the installation of a high-speed, GMP-ready five-head isolator filler to double its production capacity and target USD 130 mn revenue for its 2025 fiscal year.